Past Meeting | Keystone Symposia

This meeting took place in the past. Here is a list of meetings that are related:
Antibodies and Vaccines as Drugs for COVID-19 (2021EK31)
Antibodies as Drugs: From B Cell Biology to New Treatments (2020B1)
Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies (2019D2)

Web Desc
Antibodies as Drugs: Translating Molecules into Treatments Organizer(s): Paul W. H. I. Parren and Erica Ollmann Saphire Date: February 25 - March 01, 2018 Location: Whistler Conference Centre, Whistler, BC, Canada Sponsored by Bioverativ Therapeutics, Genentech, Inc., ImmunoGen, Inc., Merck & Co., Inc., OncoMed Pharmaceuticals, Inc., Pfizer Inc. and Regeneron Pharmaceuticals, Inc. Summary of Meeting: Antibodies carry an enormous potential in prophylaxis and treatment of human disease. Antibody therapies may be divided into two distinct but highly related disciplines. First, antibodies can be elicited de novo using vaccines. Our understanding of what constitutes an effective antibody response at the molecular level and the science of eliciting such antibodies in vivo are progressing rapidly. Secondly, isolated antibodies represent powerful drugs when developed as biopharmaceuticals, as demonstrated by the ever-expanding list of approved molecules as well as by the large number of antibody products in development in a wide range of therapeutic areas. The antibody landscape is changing as the field has moved from empirical to knowledge-based, designer approaches for which understanding of mechanisms of action at the molecular level is critical. Translating such basic knowledge into novel products and applications requires scientists from many disciplines including structural and cellular immunology, biology, engineering, chemistry and medicine to interact closely. Consequently, the field of antibody-based vaccines and therapeutics has become an interface area where experts meet and work together. The 2018 Keystone Symposia antibodies conference aims to provide a platform for knowledge-sharing from the molecular to the systems level to navigate the newest developments and insights to prevent, treat and cure major human diseases. Scholarship Deadline: October 24 2017 Discounted Abstract Deadline: October 24 2017 Abstract Deadline: November 21 2017 Discounted Registration Deadline: December 19 2017 Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting: We gratefully acknowledge additional support for this conference from: Berkeley Lights, Inc. Zymeworks We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements: EMBO Young Investigator Programme Genmab A/S ImmunoGen, Inc. Xencor, Inc. We gratefully acknowledge the generous grant for this conference provided by: National Institute of Allergy and Infectious Diseases (NIAID) Grant No. 1 R13 AI136247-01 Funding for this conference was made possible (in part) by 1 R13 AI136247-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising: Click here to view more of these organizations Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds: Click here to view more of these organizations

Web Desc

Antibodies as Drugs: Translating Molecules into Treatments

Organizer(s): Paul W. H. I. Parren and Erica Ollmann Saphire

Date: February 25 - March 01, 2018
Location: Whistler Conference Centre, Whistler, BC, Canada

Sponsored by Bioverativ Therapeutics, Genentech, Inc., ImmunoGen, Inc., Merck & Co., Inc., OncoMed Pharmaceuticals, Inc., Pfizer Inc. and Regeneron Pharmaceuticals, Inc.

Summary of Meeting:

Antibodies carry an enormous potential in prophylaxis and treatment of human disease. Antibody therapies may be divided into two distinct but highly related disciplines. First, antibodies can be elicited de novo using vaccines. Our understanding of what constitutes an effective antibody response at the molecular level and the science of eliciting such antibodies in vivo are progressing rapidly. Secondly, isolated antibodies represent powerful drugs when developed as biopharmaceuticals, as demonstrated by the ever-expanding list of approved molecules as well as by the large number of antibody products in development in a wide range of therapeutic areas. The antibody landscape is changing as the field has moved from empirical to knowledge-based, designer approaches for which understanding of mechanisms of action at the molecular level is critical. Translating such basic knowledge into novel products and applications requires scientists from many disciplines including structural and cellular immunology, biology, engineering, chemistry and medicine to interact closely. Consequently, the field of antibody-based vaccines and therapeutics has become an interface area where experts meet and work together. The 2018 Keystone Symposia antibodies conference aims to provide a platform for knowledge-sharing from the molecular to the systems level to navigate the newest developments and insights to prevent, treat and cure major human diseases.

Scholarship Deadline: October 24 2017

Discounted Abstract Deadline: October 24 2017

Abstract Deadline: November 21 2017

Discounted Registration Deadline: December 19 2017

Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:

We gratefully acknowledge additional support for this conference from:

Berkeley Lights, Inc.

Zymeworks

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

EMBO Young Investigator Programme

Genmab A/S

ImmunoGen, Inc.

Xencor, Inc.

We gratefully acknowledge the generous grant for this conference provided by:

National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1 R13 AI136247-01
Funding for this conference was made possible (in part) by 1 R13 AI136247-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program


Sunday, February 25 \| 4:00PM - 8:00PM Arrival and Registration Room: Grand Foyer
Sunday, February 25 \| 6:00PM - 8:00PM Welcome Mixer Room: Grand Foyer No registration fees are used to fund alcohol served at this function.
Monday, February 26 \| 7:00AM - 8:00AM Breakfast Room: Sea to Sky C
Monday, February 26 \| 8:00AM - 9:00AM Welcome and Keynote Address Room: Sea to Sky B Speaker 1 of 4 * Paul W. H. I. Parren, Leiden University Medical Center, Netherlands
Monday, February 26 \| 8:00AM - 9:00AM Welcome and Keynote Address Room: Sea to Sky B Speaker 2 of 4 * Erica Ollmann Saphire, La Jolla Institute for Immunology, USA
Monday, February 26 \| 8:00AM - 9:00AM Welcome and Keynote Address Room: Sea to Sky B Speaker 3 of 4 * David I. Watkins, University of Miami, USA
Monday, February 26 \| 8:00AM - 9:00AM Welcome and Keynote Address Room: Sea to Sky B Speaker 4 of 4 Dennis R. Burton, The Scripps Research Institute, USA Molecular Vaccine Design Guided by Human Anti-Viral Antibodies
Monday, February 26 \| 9:00AM - 11:30AM Protective Antibody Responses Room: Sea to Sky B Speaker 1 of 7 * David I. Watkins, University of Miami, USA
Monday, February 26 \| 9:00AM - 11:30AM Protective Antibody Responses Room: Sea to Sky B Speaker 2 of 7 George Georgiou, University of Texas at Austin, USA The Human Serological and BCR Antibody Repertoires in Cancer, Autoimmunity or following Vaccination
Monday, February 26 \| 9:00AM - 11:30AM Protective Antibody Responses Room: Sea to Sky B Coffee Break
Monday, February 26 \| 9:00AM - 11:30AM Protective Antibody Responses Room: Sea to Sky B Speaker 4 of 7 Erica Ollmann Saphire, La Jolla Institute for Immunology, USA Systematic Analysis of Monoclonal Antibodies Against Ebola Virus GP Defines Features that Contribute to Protection
Monday, February 26 \| 9:00AM - 11:30AM Protective Antibody Responses Room: Sea to Sky B Speaker 5 of 7 Antonio Lanzavecchia, Institute for Research in Biomedicine, Switzerland Lessons from the Analysis of the Immune Response to P. falciparum
Monday, February 26 \| 9:00AM - 11:30AM Protective Antibody Responses Room: Sea to Sky B Speaker 6 of 7 Arthur S. Kim, Washington University School of Medicine, USA Short Talk: Identification of Protective Antibody Epitopes on the Eastern Equine Encephalitis Virus Envelope Protein
Monday, February 26 \| 9:00AM - 11:30AM Protective Antibody Responses Room: Sea to Sky B Speaker 7 of 7 Sarah Elliott, Wistar Institute, USA Short Talk: DNA-Encoded Monoclonal Antibody (DMAb) for Acute Prophylaxis Against Influenza
Monday, February 26 \| 11:30AM - 1:00PM Poster Setup
Monday, February 26 \| 1:00PM - 10:00PM Poster Viewing Room: Grand Foyer
Monday, February 26 \| 2:30PM - 4:30PM Workshop 1: Antibodies and Protection Room: Sea to Sky B Speaker 1 of 9 * Ann J. Hessell, Oregon Health & Science University, USA
Monday, February 26 \| 2:30PM - 4:30PM Workshop 1: Antibodies and Protection Room: Sea to Sky B Speaker 2 of 9 Tongqing Zhou, NIAID, National Institutes of Health, USA Structural Basis of Zika-Neutralizing Monoclonal Antibodies Elicited in Immunized Macaque Monkeys
Monday, February 26 \| 2:30PM - 4:30PM Workshop 1: Antibodies and Protection Room: Sea to Sky B Speaker 3 of 9 Brett W. Jagger, Washington University, USA Efficacy of Zika Virus Vaccines Against Zika Infection in Mice During Pregnancy
Monday, February 26 \| 2:30PM - 4:30PM Workshop 1: Antibodies and Protection Room: Sea to Sky B Speaker 4 of 9 Laura A. Powell, Vanderbilt University, USA Cross-Reactive and Potently Neutralizing Antibody Response in a Donor Naturally Infected with Ross River Virus
Monday, February 26 \| 2:30PM - 4:30PM Workshop 1: Antibodies and Protection Room: Sea to Sky B Speaker 5 of 9 Natasha D. Durham, Tufts University, USA Neutralizing Antibodies Remodel the Conformational Landscape of Ebola GP
Monday, February 26 \| 2:30PM - 4:30PM Workshop 1: Antibodies and Protection Room: Sea to Sky B Speaker 6 of 9 Hideki Hasegawa, National Institute of Infectious Diseases, Japan Enhancement of Anti-Viral Effects of an Intranasal Inactivated Influenza Vaccine-Derived Broadly Neutralizing Antibody by IgA Polymerization
Monday, February 26 \| 2:30PM - 4:30PM Workshop 1: Antibodies and Protection Room: Sea to Sky B Speaker 7 of 9 Bryan Briney, The Scripps Research Institute, USA Exceptionally Deep Antibody Repertoire Sequencing to Guide mAb Discovery and Development
Monday, February 26 \| 2:30PM - 4:30PM Workshop 1: Antibodies and Protection Room: Sea to Sky B Speaker 8 of 9 Ron Diskin, Weizmann Institute of Science, Israel Targeting TfR1-Tropic Arenaviruses at their Achilles Heel: Structure-Based Rational Design of Universal Immunotherapy
Monday, February 26 \| 2:30PM - 4:30PM Workshop 1: Antibodies and Protection Room: Sea to Sky B Speaker 9 of 9 Matthijs M. Jore, Radboud University Medical Center, Netherlands Engineered Antibodies Against Plasmodium Transmission from Man to Mosquito
Monday, February 26 \| 4:30PM - 5:00PM Coffee Available Room: Grand Foyer
Monday, February 26 \| 5:00PM - 7:00PM From Molecules to Vaccines Room: Sea to Sky B Speaker 1 of 5 * Erica Ollmann Saphire, La Jolla Institute for Immunology, USA
Monday, February 26 \| 5:00PM - 7:00PM From Molecules to Vaccines Room: Sea to Sky B Speaker 2 of 5 Nancy L. Haigwood, Oregon Health & Science University, USA Antibody-Based HIV Therapeutics: 'Hit Early, Hit Hard'
Monday, February 26 \| 5:00PM - 7:00PM From Molecules to Vaccines Room: Sea to Sky B Speaker 3 of 5 James E. Crowe, Jr., Vanderbilt University Medical Center, USA Genetic and Structural Basis for Virus Neutralization by Human Antibodies
Monday, February 26 \| 5:00PM - 7:00PM From Molecules to Vaccines Room: Sea to Sky B Speaker 4 of 5 Robert F. Garry, Tulane University Health Sciences Center, USA Antibody Treatment of Lassa Virus: From the Field to the Lab and Back
Monday, February 26 \| 5:00PM - 7:00PM From Molecules to Vaccines Room: Sea to Sky B Speaker 5 of 5 Ruoke Wang, Tsinghua University, China Short Talk: Delineating Antibody Recognition Against Envelope Protein of Zika Virus during Natural Infection
Monday, February 26 \| 7:00PM - 8:00PM Social Hour with Lite Bites Room: Sea to Sky C No registration fees are used to fund alcohol served at this function.
Monday, February 26 \| 7:30PM - 10:00PM Poster Session 1 Room: Grand Foyer
Tuesday, February 27 \| 7:00AM - 8:00AM Breakfast Room: Sea to Sky C
Tuesday, February 27 \| 8:00AM - 11:45AM Antibodies as Biopharmaceuticals Room: Sea to Sky B Speaker 1 of 8 Janine Schuurman, Genmab B.V., Netherlands Therapeutic Antibody Panorama: Highways, Scenic Routes and Dead-Ends
Tuesday, February 27 \| 8:00AM - 11:45AM Antibodies as Biopharmaceuticals Room: Sea to Sky B Speaker 2 of 8 Karl Dane Wittrup, Massachusetts Institute of Technology, USA Principles of Effective Antibody Therapeutics
Tuesday, February 27 \| 8:00AM - 11:45AM Antibodies as Biopharmaceuticals Room: Sea to Sky B Coffee Break
Tuesday, February 27 \| 8:00AM - 11:45AM Antibodies as Biopharmaceuticals Room: Sea to Sky B Speaker 4 of 8 Marie H. Kosco-Vilbois, AC Immune, Switzerland Creating Molecules that Succeed in the Clinic
Tuesday, February 27 \| 8:00AM - 11:45AM Antibodies as Biopharmaceuticals Room: Sea to Sky B Speaker 5 of 8 Emma M. Lees, Bristol Myers Squibb, USA JTX-2011: Mechanism of Action of an Agonist Antibody Targeting ICOS
Tuesday, February 27 \| 8:00AM - 11:45AM Antibodies as Biopharmaceuticals Room: Sea to Sky B Speaker 6 of 8 * Ira Mellman, Genentech, Inc., USA Antibodies in Cancer Immunotherapy
Tuesday, February 27 \| 8:00AM - 11:45AM Antibodies as Biopharmaceuticals Room: Sea to Sky B Speaker 7 of 8 Cory Brooks, California State University, Fresno, USA Short Talk: Glycosylation of MUC1 Influences the Binding of a Therapeutic Antibody by Altering the Conformational Equilibrium of the Antigen
Tuesday, February 27 \| 8:00AM - 11:45AM Antibodies as Biopharmaceuticals Room: Sea to Sky B Speaker 8 of 8 Alexander W. Koch, Novartis Institutes for BioMedical Research, USA Short Talk: Targeting Coagulation Factor XI (FXI) for Thrombosis Prevention
Tuesday, February 27 \| 11:45AM - 5:00PM On Own for Lunch
Tuesday, February 27 \| 11:45AM - 1:00PM Poster Setup Room: Grand Foyer
Tuesday, February 27 \| 1:00PM - 10:00PM Poster Viewing Room: Grand Foyer
Tuesday, February 27 \| 4:30PM - 5:00PM Coffee Available Room: Grand Foyer
Tuesday, February 27 \| 5:00PM - 7:15PM Antibody Fc-Mediated Mechanisms I Room: Sea to Sky B Speaker 1 of 6 * Pierre Bruhns, Institut Pasteur, France
Tuesday, February 27 \| 5:00PM - 7:15PM Antibody Fc-Mediated Mechanisms I Room: Sea to Sky B Speaker 2 of 6 Pamela J. Bjorkman, California Institute of Technology, USA Structural Studies of Antibody and Receptor Binding to HIV-1 Env
Tuesday, February 27 \| 5:00PM - 7:15PM Antibody Fc-Mediated Mechanisms I Room: Sea to Sky B Speaker 3 of 6 Jan Terje Andersen, Oslo University Hospital, Norway HERA: A Human Endothelial Cell-Based Recycling Assay for Screening of FcRn Targeted Molecules
Tuesday, February 27 \| 5:00PM - 7:15PM Antibody Fc-Mediated Mechanisms I Room: Sea to Sky B Speaker 4 of 6 Jeffrey S. Miller, University of Minnesota, USA Strategies to Use Trispecific Killer Engagers to Make NK Cells Antigen Specific
Tuesday, February 27 \| 5:00PM - 7:15PM Antibody Fc-Mediated Mechanisms I Room: Sea to Sky B Speaker 5 of 6 Julie M. Fox, Washington University, USA Short Talk: Antibody Therapy Reduces Chikungunya Virus Disease through an FcgR-Dependent Mechanism
Tuesday, February 27 \| 5:00PM - 7:15PM Antibody Fc-Mediated Mechanisms I Room: Sea to Sky B Speaker 6 of 6 James A. Ernst, Genentech, Inc., USA Short Talk: Optimizing Antibodies for Targeting the Tau Protein for Alzheimer's Disease and Other Tauopathies
Tuesday, February 27 \| 7:15PM - 8:15PM Social Hour with Lite Bites Room: Sea to Sky C No registration fees are used to fund alcohol served at this function.
Tuesday, February 27 \| 7:30PM - 10:00PM Poster Session 2 Room: Grand Foyer
Wednesday, February 28 \| 7:00AM - 8:00AM Breakfast Room: Sea to Sky C
Wednesday, February 28 \| 8:00AM - 11:15AM Antibody Fc-Mediated Mechanisms II Room: Sea to Sky B Speaker 1 of 8 * Marjolein van Egmond, VU University Medical Center, Netherlands
Wednesday, February 28 \| 8:00AM - 11:15AM Antibody Fc-Mediated Mechanisms II Room: Sea to Sky B Speaker 2 of 8 Paul W. H. I. Parren, Leiden University Medical Center, Netherlands Complement Activation at the Molecular Level
Wednesday, February 28 \| 8:00AM - 11:15AM Antibody Fc-Mediated Mechanisms II Room: Sea to Sky B Speaker 3 of 8 Suzan Huberdina Maria Rooijakkers, University Medical Center Utrecht, Netherlands EMBO Young Investigator Lecture: Antibody-Mediated Killing of Bacteria by Complement
Wednesday, February 28 \| 8:00AM - 11:15AM Antibody Fc-Mediated Mechanisms II Room: Sea to Sky B Coffee Break
Wednesday, February 28 \| 8:00AM - 11:15AM Antibody Fc-Mediated Mechanisms II Room: Sea to Sky B Speaker 5 of 8 Galit Alter, MIT and Harvard University, USA Correlate Guided Approaches to Develop Antibodies Against Ebola Virus Infection
Wednesday, February 28 \| 8:00AM - 11:15AM Antibody Fc-Mediated Mechanisms II Room: Sea to Sky B Speaker 6 of 8 Pierre Bruhns, Institut Pasteur, France Analyses of Single Ab-Secreting Cells using Droplet Microfluidics
Wednesday, February 28 \| 8:00AM - 11:15AM Antibody Fc-Mediated Mechanisms II Room: Sea to Sky B Speaker 7 of 8 David P. Humphreys, UCB Pharma, UK Short Talk: On Target Hexamerisation of IgG1 Driven by a Mutant form of IgM Tail-Piece C-Terminal Fusion
Wednesday, February 28 \| 8:00AM - 11:15AM Antibody Fc-Mediated Mechanisms II Room: Sea to Sky B Speaker 8 of 8 Dieke J. van Rees, Sanquin Research and Landsteiner Laboratory, Netherlands Short Talk: Sodium Stibogluconate in Conjunction with CD47-SIRP Checkpoint Blockade Enables Rituximab-Mediated Killing of B Lymphoma Cells by Neutrophils
Wednesday, February 28 \| 11:15AM - 5:00PM On Own for Lunch
Wednesday, February 28 \| 2:30PM - 4:30PM Workshop 2: Therapeutic Antibodies Room: Sea to Sky B - Structural aspects of antibodies, novel insights - Novel therapeutic antibody formats - Novel antibody technologies - From target to therapy - Newly approved and upcoming antibody therapeutics Speaker 1 of 9 * Ida Hiemstra, Genmab, Netherlands
Wednesday, February 28 \| 2:30PM - 4:30PM Workshop 2: Therapeutic Antibodies Room: Sea to Sky B - Structural aspects of antibodies, novel insights - Novel therapeutic antibody formats - Novel antibody technologies - From target to therapy - Newly approved and upcoming antibody therapeutics Speaker 2 of 9 * Devin Sok, International AIDS Vaccine Initiative, USA Non-Human Primate Pharmacokinetics of HIV Broadly Neutralizing Antibodies Isolated from Cow Immunizations
Wednesday, February 28 \| 2:30PM - 4:30PM Workshop 2: Therapeutic Antibodies Room: Sea to Sky B - Structural aspects of antibodies, novel insights - Novel therapeutic antibody formats - Novel antibody technologies - From target to therapy - Newly approved and upcoming antibody therapeutics Speaker 3 of 9 Amarendra Pegu, NIAID, National Institutes of Health, USA Trispecific Antibodies Mediate Highly Potent and Broad Neutralization of HIV and Confer Expanded Protection Against SHIV Infection in Macaques
Wednesday, February 28 \| 2:30PM - 4:30PM Workshop 2: Therapeutic Antibodies Room: Sea to Sky B - Structural aspects of antibodies, novel insights - Novel therapeutic antibody formats - Novel antibody technologies - From target to therapy - Newly approved and upcoming antibody therapeutics Speaker 4 of 9 Sanjay Ram, University of Massachusetts, USA Potentiation of Efficacy of a Candidate Immunotherapeutic Anti-Neisseria Gonorrhoeae Antibody by Enhancing IgG Fc Hexamer Formation
Wednesday, February 28 \| 2:30PM - 4:30PM Workshop 2: Therapeutic Antibodies Room: Sea to Sky B - Structural aspects of antibodies, novel insights - Novel therapeutic antibody formats - Novel antibody technologies - From target to therapy - Newly approved and upcoming antibody therapeutics Speaker 5 of 9 Nina G. Caculitan, Genentech, Inc., USA Discovery of the Determinants of Antibody-Drug Conjugate Efficacy and a Novel Resistance Mechanism to Anti-HER2 Therapeutics
Wednesday, February 28 \| 2:30PM - 4:30PM Workshop 2: Therapeutic Antibodies Room: Sea to Sky B - Structural aspects of antibodies, novel insights - Novel therapeutic antibody formats - Novel antibody technologies - From target to therapy - Newly approved and upcoming antibody therapeutics Speaker 6 of 9 Jordana Griffiths, University of Southampton, UK Targeting OX40 in Cancer Immunotherapy
Wednesday, February 28 \| 2:30PM - 4:30PM Workshop 2: Therapeutic Antibodies Room: Sea to Sky B - Structural aspects of antibodies, novel insights - Novel therapeutic antibody formats - Novel antibody technologies - From target to therapy - Newly approved and upcoming antibody therapeutics Speaker 7 of 9 John Engelhardt, Bristol-Myers Squibb Company, USA Next Generation Anti-CTLA-4 Antibodies
Wednesday, February 28 \| 2:30PM - 4:30PM Workshop 2: Therapeutic Antibodies Room: Sea to Sky B - Structural aspects of antibodies, novel insights - Novel therapeutic antibody formats - Novel antibody technologies - From target to therapy - Newly approved and upcoming antibody therapeutics Speaker 8 of 9 Ezio Bonvini, MacroGenics, Inc, USA Tailoring Cytolytic Activity, Proliferation and Cytokine Release via CD3 Engineering of DART® Molecules for Redirected T-cell Killing
Wednesday, February 28 \| 2:30PM - 4:30PM Workshop 2: Therapeutic Antibodies Room: Sea to Sky B - Structural aspects of antibodies, novel insights - Novel therapeutic antibody formats - Novel antibody technologies - From target to therapy - Newly approved and upcoming antibody therapeutics Speaker 9 of 9 Michael Johnston, Queen's University Belfast, UK Development of AMG 655 Conjugated Polymeric Nanoparticles Targeting Death Receptor 5 for the Treatment of Pancreatic Cancer
Wednesday, February 28 \| 4:30PM - 5:00PM Coffee Available Room: Grand Foyer
Wednesday, February 28 \| 5:00PM - 7:00PM Exploiting Effector Cell Responses Room: Sea to Sky B Speaker 1 of 5 * Pamela J. Bjorkman, California Institute of Technology, USA
Wednesday, February 28 \| 5:00PM - 7:00PM Exploiting Effector Cell Responses Room: Sea to Sky B Speaker 2 of 5 Sergio A. Quezada, University College London, UK Regulatory T Cells, Polymorphisms and Response to Checkpoint Blockade: From Mechanisms to Potential Biomarkers
Wednesday, February 28 \| 5:00PM - 7:00PM Exploiting Effector Cell Responses Room: Sea to Sky B Speaker 3 of 5 Bertrand Routy, Centre hospitalier de l’Université de Montréal, Canada The Gut Microbiota as a Novel Predictor of Immune Checkpoint Inhibitors Response?
Wednesday, February 28 \| 5:00PM - 7:00PM Exploiting Effector Cell Responses Room: Sea to Sky B Speaker 4 of 5 Marjolein van Egmond, VU University Medical Center, Netherlands Translating Antibody–Effector Cell Cross-Talk to Immunotherapy
Wednesday, February 28 \| 5:00PM - 7:00PM Exploiting Effector Cell Responses Room: Sea to Sky B Speaker 5 of 5 Maria Mar Naranjo, Centre National de la Recherche Scientifique, France Short Talk: Key Immunomodulatory Role of Neutrophils in the Induction of Protective Immunity by Antiviral Monoclonal Antibodies
Wednesday, February 28 \| 7:00PM - 8:00PM Social Hour with Lite Bites Room: Sea to Sky C No registration fees are used to fund alcohol served at this function.
Thursday, March 01 \| 7:00AM - 8:00AM Breakfast Room: Sea to Sky C
Thursday, March 01 \| 8:00AM - 11:15AM Novel Ways to Deliver Antibody Therapy Room: Sea to Sky B Speaker 1 of 8 * Janine Schuurman, Genmab B.V., Netherlands
Thursday, March 01 \| 8:00AM - 11:15AM Novel Ways to Deliver Antibody Therapy Room: Sea to Sky B Speaker 2 of 8 Ugur Sahin, BioNTech AG, Germany Antibody and mRNA-Based Therapeutics
Thursday, March 01 \| 8:00AM - 11:15AM Novel Ways to Deliver Antibody Therapy Room: Sea to Sky B Speaker 3 of 8 Mark Cobbold, AstraZeneca, USA Retargeting T Cells for Tumor Therapy
Thursday, March 01 \| 8:00AM - 11:15AM Novel Ways to Deliver Antibody Therapy Room: Sea to Sky B Coffee Break
Thursday, March 01 \| 8:00AM - 11:15AM Novel Ways to Deliver Antibody Therapy Room: Sea to Sky B Speaker 5 of 8 Markus Schmid, University of Zurich, Switzerland Paracrine Delivery of Therapeutic Proteins
Thursday, March 01 \| 8:00AM - 11:15AM Novel Ways to Deliver Antibody Therapy Room: Sea to Sky B Speaker 6 of 8 Johannes Lutz, Curevac AG, Germany mRNA-Encoded Antibodies for Passive Immunization
Thursday, March 01 \| 8:00AM - 11:15AM Novel Ways to Deliver Antibody Therapy Room: Sea to Sky B Speaker 7 of 8 Kalie Mix, Sanofi, USA Short Talk: Cytosolic Delivery of Antibodies
Thursday, March 01 \| 8:00AM - 11:15AM Novel Ways to Deliver Antibody Therapy Room: Sea to Sky B Speaker 8 of 8 Jeffrey J. Bunker, University of Chicago, USA Short Talk: Natural Polyreactive IgA Antibodies Coat the Intestinal Microbiota
Thursday, March 01 \| 11:15AM - 5:00PM On Own for Lunch
Thursday, March 01 \| 4:30PM - 5:00PM Coffee Available Room: Grand Foyer
Thursday, March 01 \| 5:00PM - 6:45PM From Molecules to the Clinic Room: Sea to Sky B Speaker 1 of 3 * Paul W. H. I. Parren, Leiden University Medical Center, Netherlands
Thursday, March 01 \| 5:00PM - 6:45PM From Molecules to the Clinic Room: Sea to Sky B Speaker 2 of 3 David E. Szymkowski, Szymkowski David, USA Exploring Novel Mechanisms of Action and Clinical Outcomes of Therapeutic Antibodies Fc-Engineered to Optimally Engage Fc Gamma RIIb
Thursday, March 01 \| 5:00PM - 6:45PM From Molecules to the Clinic Room: Sea to Sky B Speaker 3 of 3 John M. Lambert, USA Antibody-Drug Conjugates (ADCs): The Magic Bullet Revisited
Thursday, March 01 \| 6:45PM - 7:00PM Meeting Wrap-Up: Outcomes and Future Directions (Organizers) Room: Sea to Sky B
Thursday, March 01 \| 7:00PM - 8:00PM Social Hour with Lite Bites Room: Sea to Sky C No registration fees are used to fund alcohol served at this function.
Thursday, March 01 \| 8:00PM - 11:00PM Entertainment Room: Sea to Sky C Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
Thursday, March 01 \| 8:00PM - 11:00PM Cash Bar Room: Sea to Sky C
Friday, March 02 \| 10:24AM - 10:24AM Departure *Session Chair.